- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer (la/mUC)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 516KB)
Enfortumab vedotin – November 2024
Enfortumab Vedotin; Powder for I.V. infusion 20 mg, Powder for I.V. infusion 30 mg; Padcev®
Last updated
30 May 2025